Important Notice for Humacyte, Inc. Investors
Levi & Korsinsky, LLP has reached out to individuals invested in Humacyte, Inc. (NASDAQ: HUMA) regarding a class action lawsuit that is essential for those affected. This lawsuit represents an effort to recover losses suffered by shareholders due to alleged securities fraud.
Understanding the Class Action Lawsuit
This class action is aimed at Humacyte, Inc. investors whose interests have been negatively impacted within a set time frame. Specifically, the lawsuit targets issues that arose between May 10, 2024, and October 17, 2024, when various disclosures reveal potential misrepresentation from the company.
What’s at Stake?
The lawsuit claims that the Company provided misleading information regarding its operations. Allegations include that Humacyte's facility did not meet the necessary manufacturing requirements and that the FDA’s review processes would be delayed as the Company worked to rectify these issues. Consequently, these factors raised significant concerns regarding the likelihood of receiving FDA approval for an essential product intended for vascular trauma scenarios.
Critical Deadline for Investors
For those who believe they may have been impacted, a crucial deadline looms. Investors who suffered a loss during the outlined period have until January 17, 2025, to request to be appointed as a lead plaintiff in this class action. Being a lead plaintiff is not a prerequisite for claiming any recovery; participation is open to all impacted shareholders.
No Costs Involved
Class members should note that participation in this class action comes with no out-of-pocket costs. Investors are encouraged to consider their options without worrying about incurring additional fees.
Why Choose Levi & Korsinsky
Levi & Korsinsky has a notable track record over the last two decades in securing significant settlements for shareholders. With a dedicated team of over 70 professionals, the firm specializes in complex securities litigation, continually recognized as a leading entity in the field. Its reputation is built on the foundation of trust, dedication, and a commitment to fighting for the rights of investors.
Contact Information
If you need further information or support regarding this matter, you can reach out directly to Joseph E. Levi, Esq. For inquiries, provide your details through the contact number or email provided below:
Contact:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Contact via Email
Frequently Asked Questions
What is the purpose of this class action lawsuit?
The lawsuit aims to recover losses for shareholders impacted by alleged securities fraud during a specific time period related to Humacyte, Inc.
How can I participate in this class action?
If you believe you have been affected, you can request to be appointed as a lead plaintiff by January 17, 2025, or simply remain part of the class without serving as a lead plaintiff.
Are there any costs associated with joining this lawsuit?
No, if you are a member of the class, you may be entitled to compensation without paying any fees or costs upfront.
Who are Levi & Korsinsky?
Levi & Korsinsky, LLP is a well-established law firm specializing in securities litigation, known for its track record and extensive experience in the field.
How can I contact Levi & Korsinsky?
You can reach them at their New York office or via email for any further inquiries regarding the lawsuit.
